Usefulness of non-high-density lipoprotein cholesterol determinations in the diagnosis and treatment of dyslipidemia
| Autor: | Glenn A. Hirsch, Roger S. Blumenthal |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Very low-density lipoprotein
medicine.medical_specialty Apolipoprotein B Lipoproteins Hyperlipidemias Coronary Artery Disease chemistry.chemical_compound Internal medicine Medicine Humans Apolipoproteins B biology business.industry Cholesterol Non high density lipoprotein cholesterol Cholesterol HDL Atherosclerotic disease nutritional and metabolic diseases Disease Management Cholesterol LDL medicine.disease Coronary heart disease Endocrinology chemistry Practice Guidelines as Topic Cardiology biology.protein lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Dyslipidemia Lipoprotein |
| Zdroj: | The American journal of cardiology. 91(7) |
| ISSN: | 0002-9149 |
| Popis: | N lipoprotein (non-HDL) cholesterol, calculated as total cholesterol minus highdensity lipoprotein (HDL) cholesterol, encompasses the apolipoprotein B (Apo B)–containing particles that promote atherosclerosis, including low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, lipoprotein (a), and intermediate-density lipoprotein cholesterol; therefore, it may represent an accurate marker for coronary heart disease (CHD) risk. The Adult Treatment Panel (ATP) III guidelines have introduced non-HDL cholesterol as a secondary target of therapy for patients with elevated levels of triglycerides.1 The aim of this review was to compare LDL and non-HDL cholesterol as markers of atherosclerotic disease and to discuss treatment options for reducing non-HDL cholesterol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect